Live Earnings: Will Tempus AI Surprise Wall Street Tonight?

We are updating this story in real time as new information breaks. Stay on this page for the latest developments, key quotes, numbers, and market reaction as they happen.

24/7 Wall Street • 5 hours ago

Tempus AI Stock Drops Despite Q4 Earnings Beat: Details

Tempus AI, Inc. (NASDAQ:TEM) shares fell in Tuesday's extended trading after the company released its fourth-quarter earnings report, despite beating estimates on the top and bottom lines.

Benzinga • 3 hours ago

Tempus Reports Fourth Quarter and Full Year 2025 Results

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter and year ended December 31, 2025. Fourth quarter revenue of $367.2 million, up 83.0% year-over-year with 33.5% organic growth (excluding Ambry) Diagnostics revenue of $266.9 million in the fourth quarter, representing 121.6% growth year-over-year, driven by Oncology volume growth of 29% and Hered.

Business Wire • 4 hours ago

Here's How Tempus AI Is Tapping the Imagining Space

TEM expands into radiology via Median partnership, adding AI lung screening to Pixel as FDA clearance and past deals boost imaging push.

Zacks Investment Research • Feb 23, 2026

AI-Driven Innovation Accelerates Tempus AI's Expansion Across MedTech

TEM rolls out new AI tools across oncology, cardiology and mental health, accelerating its push to reshape MedTech innovation.

Zacks Investment Research • Feb 20, 2026

Is TEM Stock A Buy At $60?

Tempus AI (NASDAQ: TEM) trades at a premium by traditional metrics, remains unprofitable on a GAAP basis, and has spent the past week benefiting from strong analyst optimism. So why might the stock still appear attractive at $60?

Forbes • Feb 19, 2026

Unlocking Q4 Potential of Tempus (TEM): Exploring Wall Street Estimates for Key Metrics

Get a deeper insight into the potential performance of Tempus (TEM) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Zacks Investment Research • Feb 19, 2026

Why Tempus AI Stock Is Up Today — And What to Watch Before Next Week's Earnings

Tempus AI, Inc. (NASDAQ:TEM) shares are climbing today after the company unveiled a new AI-powered cancer diagnostic algorithm, building momentum ahead of its Q4 2025 earnings report scheduled for February 24, 2026 after market close.

24/7 Wall Street • Feb 18, 2026

Tempus AI Stock Before Q4 Earnings Release: To Buy or Not to Buy?

TEM heads into Q4 earnings with expected 82.8% revenue growth, rising oncology momentum and a premium valuation clouding near-term upside.

Zacks Investment Research • Feb 18, 2026

Tempus Announces Novel Pan-Cancer HRD-RNA Algorithm

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of its new HRD-RNA algorithm. This next-generation model represents a significant improvement in identifying Homologous Recombination Deficiency (HRD), providing a more robust, functional assessment of tumor biology compared to traditional static DNA-based assays. Tempus HRD-RNA is an AI-driven, 1,660-gene logistic regression model de.

Business Wire • Feb 18, 2026